Read More

FDA Approves Merck’s Drug Belzutifan For Type Of Advanced Kidney Cancer In Pretreated Cancer Patients

The FDA approved Merck & Co Inc's (NYSE: MRK) Welireg (belzutifan), an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, for adult patients with advanced renal cell carcinoma (RCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and

MRK

Read More

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment At Stanford Medicine; FemBloc Is Being Developed As A First- Of-Its-Kind, Non-Surgical Permanent Birth Control With A Clearly Defined U.S. Regulatory Pathway

- Stanford Medicine, a center with a long tradition of leadership in pioneering gynecological research and innovation, is the second academic center to participate in the FemBloc pivotal trial since enrollment began last

FEMY